Media headlines about Acceleron Pharma (NASDAQ:XLRN) have trended somewhat positive on Saturday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acceleron Pharma earned a news impact score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.275354826902 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Acceleron Pharma (NASDAQ XLRN) opened at $35.92 on Friday. Acceleron Pharma has a one year low of $23.07 and a one year high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The business had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.52 million. During the same period in the prior year, the business earned ($0.55) earnings per share. The business’s quarterly revenue was up .0% on a year-over-year basis. equities analysts expect that Acceleron Pharma will post -2.65 earnings per share for the current year.

Several research analysts have recently issued reports on XLRN shares. HC Wainwright increased their price objective on shares of Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a report on Monday, December 11th. Cann reiterated a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. Barclays increased their price objective on shares of Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, September 20th. Finally, UBS reiterated a “buy” rating and issued a $50.00 price objective (up from $36.00) on shares of Acceleron Pharma in a report on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $44.56.

In other news, major shareholder Corp /De/ Celgene purchased 745,592 shares of Acceleron Pharma stock in a transaction that occurred on Monday, September 25th. The stock was acquired at an average price of $37.00 per share, for a total transaction of $27,586,904.00. Following the transaction, the insider now owns 6,118,479 shares in the company, valued at $226,383,723. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.90% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with's FREE daily email newsletter.